Zevra Therapeutics (ZVRA) Change in Cash (2014 - 2026)

Zevra Therapeutics has reported Change in Cash for 13 years, with the latest figure at $33.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash rose 833.59% year-over-year to $33.2 million; the trailing twelve-month figure through Mar 2026 stood at $58.3 million (up 1157.45% YoY), and the FY2025 full-year result was $28.6 million, up 408.95% from the prior year.
• Change in Cash for Q1 2026 stood at $33.2 million, up from $8.0 million in the prior quarter.
• The five-year high for Change in Cash was $33.2 million in Q1 2026, with the low at -$25.3 million in Q1 2023.
• Historically, Change in Cash has averaged -$985352.9 across 5 years, with a median of -$220000.0 in 2023.
• Annual changes were most pronounced in 2024 — Change in Cash sank 9106.36% — and 2025, when it surged 1877.5%.
• Zevra Therapeutics' Change in Cash stood at -$4.7 million in 2022, then jumped by 95.28% to -$220000.0 in 2023, then slumped by 9106.36% to -$20.3 million in 2024, then surged by 139.34% to $8.0 million in 2025, then jumped by 316.58% to $33.2 million in 2026.
• The last three Change in Cash figures came in at $33.2 million (Q1 2026), $8.0 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.